Sebastián Arguedas-Chacón

Dr. Sebastián Arguedas-Chacón

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
BSBruno Serrano-Arias
Bruno Serrano-Arias
AAAdriana Araya-Zúñiga
Adriana Araya-Zúñiga
JWJohan Waterhouse-Garbanzo
Johan Waterhouse-Garbanzo
ZRZoe Rojas-Barrantes
Zoe Rojas-Barrantes
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
KCKevin José Cruz-Mora
Kevin José Cruz-Mora

21 May 2025 in Dermato
Verified
Journal Article
Open access
PDF file
EMErnesto Martínez-Vargas
Ernesto Martínez-Vargas
JMJeaustin Arón Mora
Jeaustin Arón Mora
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
JHJosephine Hernández-López
Josephine Hernández-López
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
Background: Artificial intelligence (AI) has emerged as a transformative tool in modern medicine, particularly in dermatology, where it supports the diagnosis and management of various skin diseases, including skin cancer. Through machine learning and deep learning techniques, AI enables accurate analysis of clinical and dermoscopic images, improving early detection and clinical outcomes. Objective: This systematic review aimed to evaluate the clinical applications of AI in dermatology, focusing on its impact on diagnostic accuracy, workflow efficiency, and access to specialized care. Methods: The review was conducted according to PRISMA guidelines. Peer-reviewed studies published between January 2020 and March 2025 in English or Spanish were included if they evaluated AI-based tools for dermatological diagnosis, classification, or treatment. Animal studies, editorials, non-peer-reviewed articles, and studies with an unclear methodology were excluded. A comprehensive search was performed in PubMed, Scopus, IEEE Xplore, and Google Scholar between December 2024 and March 2025. The risk of bias was assessed qualitatively, using a tailored framework based on study design, dataset transparency, and clinical applicability. Results: A total of 29 studies met the inclusion criteria. AI tools demonstrated high performance in melanoma detection, achieving up to 90% accuracy and 85% sensitivity. In clinical settings, AI support reduced mismanagement of malignant lesions from 58.8% to 4.1% and avoided 27% of unnecessary procedures in benign cases. Additional tools such as convolutional neural networks and imaging systems like FotoFinder also showed promising results. Limitations: Limitations of the evidence include the heterogeneity of AI models, lack of external validation, and a moderate-to-high risk of bias. Conclusions: AI has demonstrated robust clinical potential in dermatology, particularly in cancer detection and workflow optimization. However, further studies are required to address challenges such as algorithmic bias, data privacy, and regulatory oversight. Funding and registration: This review received no external funding and was not registered in a systematic review registry.

1 January 2024 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
AQAlonso Quirós-Romero
Alonso Quirós-Romero
Jose Miguel Chaverri-FernandezJose Miguel Chaverri-Fernandez
Jose Miguel Chaverri-Fernandez
BSBruno Serrano-Arias
Bruno Serrano-Arias
MSMario Speranza
Mario Speranza
Zavaleta-Monestel E, et al. Int J Heart Fail. 2024 Jan;6(1):1-10. https://doi.org/10.36628/ijhf.2023.0022

28 October 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
JDJosé M Díaz-Madriz
José M Díaz-Madriz
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JVJorge Arturo Villalobos-Madriz
Jorge Arturo Villalobos-Madriz
CRCarolina Rojas-Chinchilla
Carolina Rojas-Chinchilla
PCPriscilla Castrillo
Priscilla Castrillo
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
This study aims to characterize the impact of the implementation of an antimicrobial stewardship program (AMS) on the optimal selection of surgical antibiotic prophylaxis in adult patients. This is a retrospective quasi-experimental study that compared the selection and duration of antibiotics for all surgical prophylaxis prescriptions over six months, both before (pre-AMS) and after a five-year intervention of AMS (post-AMS). In addition, data related to the consumption of antibiotics, adverse drug reactions, and surgical site infections throughout the years of the intervention were analyzed. The rate of appropriate selection of antibiotic prophylaxis in surgical procedures improved to 80% during the post-AMS period. The percentage of optimal duration increased from 69.1% (N = 1598) in the pre-AMS period to 78.0% (N = 841) in the post-AMS period (p < 0.001). The consumption of ceftriaxone significantly decreased, while the use of cefazolin increased more than nine times. No severe adverse reactions or increases in surgical site infections were detected after the intervention. The implementation of an AMS in the surgical ward demonstrated a trend towards a positive overall impact on the selection and duration of prophylactic antibiotics for surgery, with positive results also observed in other variables associated with the prescription of these antibiotics.

13 October 2022 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
JDJosé Pablo Díaz‐Madriz
José Pablo Díaz‐Madriz
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
JCJosé Miguel Chaverri‐Fernández
José Miguel Chaverri‐Fernández
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
RARaquel Arguedas‐Herrera
Raquel Arguedas‐Herrera
GMGabriel Muñoz‐Gutiérrez
Gabriel Muñoz‐Gutiérrez

12 December 2023 in Bacteria
Verified
Journal Article
Open access
PDF file
JDJosé M Díaz-Madriz
José M Díaz-Madriz
KCKevin José Cruz-Mora
Kevin José Cruz-Mora
CRCarolina Rojas-Chinchilla
Carolina Rojas-Chinchilla
Sebastián Arguedas-ChacónSebastián Arguedas-Chacón
Sebastián Arguedas-Chacón
BSBruno Serrano-Arias
Bruno Serrano-Arias
CRCesar Rodriguez
Cesar Rodriguez
(1) Background: Given the widespread use of Alkalihalobacillus clausii (A. clausii) as a probiotic in recent decades and the detection of bacteremia cases in a group of patients, we sought to analyze cases of A. clausii bacteremia following oral probiotic use (2) Methods: A retrospective observational study was conducted at a private hospital in San Jose, Costa Rica. Cases of bacteremia caused by A. clausii confirmed by the microbiology laboratory were analyzed in patients who received oral treatment with this probiotic between January 2020 and January 2022. In addition, an isolate (HCB-AC2) was compared through whole genome sequencing to demonstrate the correlation of bacteremia and A. clausii. Possible vulnerability factors related to the development of this condition were determined. (3) Results: Four cases were identified in this hospital over 2 years. Genomic analysis of isolate HCB-AC2, using two different methods, showed identical results. This indicates that HCB-AC2 is genomically identical to ENTpro and the Enterogermina® reference genome. The median age was 71 years, and all patients had some degree of immunosuppression. All patients met at least three sepsis criteria at the time of bacterial identification. Most patients were treated with vancomycin and levofloxacin. Three of the identified patients died. (4) Conclusion: A. clausii can be used as a probiotic, but caution is advised when used in immunosuppressed and elderly patients. These findings align with those reported in similar case studies.